SG/CALL/AMGEN/310/0.1/21.06.24 Stock

DE000SQ3S4W5

Market Closed - Deutsche Boerse AG 13:04:52 2024-06-13 EDT
0.064 ^EUR	-41.82%

Current month	-84.39%
1 month	-90.45%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart AMGEN INC.

Latest news about AMGEN INC.

Amgen Gets FDA Approval to Treat Aggressive Leukemia Type with Blincyto	06-14	DJ
Amgen : Continues to Propel BiTE® Technology Innovation	06-14	PU
Amgen Says FDA Approves Blincyto to Treat Type of Blood Cancer	06-14	MT
FDA APPROVES BLINCYTO® (BLINATUMOMAB) IN CD19-POSITIVE PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) IN THE CONSOLIDATION PHASE	06-14	PR

More news

Quotes 5-day view

Date	Price	Change
24-06-13	0.064	-41.82%
24-06-12	0.11	-21.43%
24-06-11	0.14	-36.36%
24-06-10	0.22	-26.67%
24-06-07	0.3	-21.05%

Delayed Quote Deutsche Boerse AG

Last update June 13, 2024 at 01:04 pm

More quotes

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	AMGEN INC.
Issuer	Société Générale
WKN	SQ3S4W
ISIN	DE000SQ3S4W5
Date issued	2022-11-03
Strike	310 $
Maturity	2024-06-21 (5 Days)
Parity	10 : 1
Emission price	2.58 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	3.77 €
Lowest since issue	0.05 €
Spread	0.045 €
Spread %	40.91%

Company Profile

Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other (5.8%): primarily royalties. The United States account for 70.3% of net sales.

Sector

More about the company

Ratings for Amgen Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Consensus: Amgen Inc.

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

298.6 USD

Average target price

316.4 USD

Spread / Average Target

+5.97%

Consensus